MEDVi vs SkinnyRx: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
MEDVi beats SkinnyRx overall, scoring 7.7/10 vs 7.3/10. SkinnyRx is more affordable at $199/mo vs $299/mo. Choose MEDVi for users who want a low entry price with oral and injectable co. Choose SkinnyRx for users who want flexibility in compounded glp-1 medication fo.
A side-by-side comparison of MEDVi and SkinnyRx covering pricing, scores, medication types, insurance, and more to help you decide.
MEDVi
#22 of 47MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake — one of the broader compounded mixes among independent telehealth providers in 2026.
Visit MEDViSkinnyRx
#36 of 47Direct-to-consumer telehealth platform offering compounded GLP-1 medications across five formats — injectable and sublingual semaglutide, semaglutide tablets, and tirzepatide as either injectable or tablets. Operated by Lean Rx, Inc. (Sacramento, CA). Compounded only — does not prescribe brand-name Wegovy/Zepbound/Ozempic/Mounjaro. Cash-pay only with HSA/FSA accepted; does not bill insurance. 4,100+ Trustpilot reviews at 4.8 stars.
Visit SkinnyRx| Feature | MEDVi | SkinnyRx |
|---|---|---|
| Our Score | 7.7/10 | 7.3/10 |
| Starting Price | $299/mo | $199/mo |
| Medication Type | Both | Compounded |
| Insurance Accepted | No | No |
| Best For | Users who want a low entry price with oral and injectable compounded options | Users who want flexibility in compounded GLP-1 medication format (injectable, sublingual, or tablet) at a mid-tier price point |
| Ranking | #22 | #36 |
Pros & Cons Compared
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179/mo is competitive for a platform with both oral and injectable compounded formulations
Cons
- −Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
SkinnyRx
Pros
- +Five medication formats — the broadest compounded-GLP-1 menu in DTC telehealth, including the rare oral tirzepatide tablet that almost no competitor offers
- +$199/mo entry price for both injectable and sublingual semaglutide is competitive in the mid-tier compounded segment
- +Fast onboarding: 5–10 minute online questionnaire, physician review in 24–48 hours, medication delivered in 3–7 business days with temperature-controlled shipping
- +4,100+ Trustpilot reviews at 4.8 stars — among the strongest aggregate social-proof signals in the GLP-1 telehealth category
Cons
- −No brand-name FDA-approved options (Wegovy, Zepbound, Ozempic, Mounjaro) — compounded-only model limits patients who want or need an FDA-approved finished product
- −Limited public transparency: founders, executive team, medical director, and specific compounding-pharmacy partners are not named on the public site
- −Cash-pay only — does not bill commercial insurance, Medicare, or Medicaid (HSA/FSA payments accepted)
- −Independent reviews flag inconsistent customer-service responsiveness, which is a real concern for a medication that requires titration support and dose-adjustment dialogue
Our Verdict
MEDVi edges out SkinnyRx with a score of 7.7/10 vs 7.3/10. If budget is your priority, SkinnyRx starts at $199/mo compared to MEDVi's $299/mo. MEDVi offers both brand-name and compounded medications, giving you more flexibility. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options. Choose SkinnyRx if you want: users who want flexibility in compounded glp-1 medication format (injectable, sublingual, or tablet) at a mid-tier price point.